Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Alendronate MicroCT Study
NCT00293813Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2006
- Primary completion
- Mar 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of denosumab in postmenopausal osteoporosis (3 arms), sponsored by Amgen. Primary endpoint: Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12. Started May 2006; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00293813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293813.